Literature DB >> 31926810

Intermittent theta burst stimulation (iTBS) adjustment effects of schizophrenia: Results from an exploratory outcome of a randomized double-blind controlled study.

Lu Wang1, Xingui Chen1, Yang Wu2, Kongliang He3, Feifei Xu2, Guixian Xiao1, Panpan Hu1, Bensheng Qiu4, Gong-Jun Ji5, Kai Wang6.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 31926810     DOI： 10.1016/j.schres.2019.12.008

Source DB:  PubMed          Journal:  Schizophr Res        ISSN： 0920-9964            Impact factor:   4.939


× No keyword cloud information.
  5 in total

Review 1.  The efficacy of transcranial magnetic stimulation (TMS) for negative symptoms in schizophrenia: a systematic review and meta-analysis.

Authors:  Rasmus Lorentzen; Tuan D Nguyen; Alexander McGirr; Fredrik Hieronymus; Søren D Østergaard
Journal:  Schizophrenia (Heidelb)       Date:  2022-04-09

2.  Rationale and study design of a trial to assess rTMS add-on value for the amelioration of negative symptoms of schizophrenia (RADOVAN).

Authors:  T Hebel; B Langguth; M Schecklmann; S Schoisswohl; S Staudinger; A Schiller; L Ustohal; T Sverak; M Horky; T Kasparek; T Skront; M Hyza; T B Poeppl; M L Riester; L Schwemmer; S Zimmermann; K Sakreida
Journal:  Contemp Clin Trials Commun       Date:  2022-01-20

3.  Optimized Magnetic Stimulation Induced Hypoconnectivity Within the Executive Control Network Yields Cognition Improvements in Alzheimer's Patients.

Authors:  Guixian Xiao; Yue Wu; Yibing Yan; Liying Gao; Zhi Geng; Bensheng Qiu; Shanshan Zhou; Gongjun Ji; Xingqi Wu; Panpan Hu; Kai Wang
Journal:  Front Aging Neurosci       Date:  2022-03-15       Impact factor: 5.750

4.  Efficacy and safety of intermittent theta-burst stimulation in patients with schizophrenia: A meta-analysis of randomized sham-controlled trials.

Authors:  Kah Kheng Goh; Chun-Hsin Chen; Tzu-Hua Wu; Yi-Hang Chiu; Mong-Liang Lu
Journal:  Front Pharmacol       Date:  2022-08-22       Impact factor: 5.988

5.  Intermittent Theta Burst Stimulation (iTBS) as an Optimal Treatment for Schizophrenia Risk Decision: an ERSP Study.

Authors:  Yang Wu; Lu Wang; Fengqiong Yu; Gong-Jun Ji; Guixian Xiao; Xu Feifei; Zhu Chunyan; Chen Xingui; Kai Wang
Journal:  Front Psychiatry       Date:  2021-05-10       Impact factor: 4.157
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.